CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Cholesterol metabolism modulation facilitates CAR-T induced killing of ovarian cancer.
Cholesterol metabolism modulation facilitates CAR-T induced killing of ovarian cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
未标注摘要:卵巢癌是全球致死率最高的妇科癌症之一,复发率也居高不下。近期开发的CAR-T(CAR-T)细胞疗法对血液系统恶性肿瘤显示出强效临床疗效。
然而,卵巢癌在内的实体瘤存在多种抑制T细胞活性的机制;研究显示,癌细胞代谢改变会导致其抵抗免疫细胞对实体瘤的攻击。在此,我们利用无标记高内涵高光谱受激拉曼散射(h2SRS)成像,探究卵巢癌细胞面对CAR-T 细胞攻击时的代谢应答。通过空间分辨率显著提高的可视化h2SRS成像,我们发现,CAR-T 治疗后存活的卵巢癌细胞胆固醇代谢发生改变,表现为胆固醇酯在脂滴中储存增加及游离胆固醇增加。使用胆固醇酯化抑制剂Avasimibe可进一步增强CAR-T 细胞毒性。
我们的研究显示,调节代谢以促进CAR-T 细胞治疗实体瘤具有潜力。意义说明:卵巢癌是重要的全球健康挑战,主要因为化疗耐药会导致疾病复发。与此同时,CAR-T 等免疫疗法已革新血液癌症治疗,但其用于卵巢癌等实体瘤仍受疗效有限所阻碍。
本研究利用高内涵受激拉曼散射(SRS)成像,揭示有助于卵巢癌细胞抵抗CAR-T 介导细胞毒作用的代谢适应。基于这些发现,我们采用代谢干预增强CAR-T 细胞毒性。该方法揭示了卵巢癌的治疗脆弱性,并展示了一种可能适用于克服实体瘤耐药的研究策略。
UNLABELLED: Ovarian cancer is one of the most lethal gynecological cancers worldwide and has one of the highest recurrence rates. Recently developed Chimeric Antigen Receptor T (CAR-T) cell therapy has shown potent clinical efficacy against hematological malignancies.
However, solid tumors, including ovarian cancer, possess several mechanisms that hinder T cell activity, and metabolic alteration of cancer cells has been shown to contribute to resistance to immune cell attack against solid tumors.
Here, we explored the metabolic response of ovarian cancer cells to CAR-T cell attack using label-free high-content hyperspectral stimulated Raman scattering (h 2 SRS) imaging. Utilizing visible h 2 SRS imaging with much improved spatial resolution, we found an altered cholesterol metabolism, featured by increased storage of cholesteryl ester in lipid droplets and free cholesterol, in ovarian cancer cells that survived the CAR-T treatment. Administration of Avasimibe, an inhibitor of cholesteryl esterification, further enhanced CAR-T cytotoxicity.
Our study shows the promise of implementing metabolic modulation to facilitate CAR-T cell treatment of solid tumors. SIGNIFICANCE STATEMENT: Ovarian cancer is a major global health challenge, mainly due to relapse driven by chemotherapy resistance development. Meanwhile, immunotherapies such as CAR-T have revolutionized treatment for blood cancers, but their application in solid tumors like ovarian cancer is hindered by limited efficacy.
This study uses high-content stimulated Raman scattering (SRS) imaging to reveal metabolic adaptations that help ovarian cancer cells survive CAR-T-mediated cytotoxicity. Guided by these insights, we apply metabolic interventions that enhance CAR-T cytotoxicity efficacy. This approach reveals therapeutic vulnerabilities in ovarian cancer and demonstrates an investigative strategy applicable for overcoming resistance in solid tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。